Patient characteristics by treatment arm among those with a baseline HRQoL evaluation
| . | Treatment arm . | . | |
|---|---|---|---|
| DEC (n = 279) . | 3+7 (n = 270) . | Total (N = 549) . | |
| n (%) . | n (%) . | n (%) . | |
| Age, y | |||
| n | 279 (100.0) | 270 (100.0) | 549 (100.0) |
| 60-64 | 66 (23.7) | 65 (24.1) | 131 (23.9) |
| 65-69 | 119 (42.7) | 112 (41.5) | 231 (42.1) |
| ≥70 | 94 (33.7) | 93 (34.4) | 187 (34.1) |
| Sex | |||
| n | 278 (99.6) | 269 (99.6) | 547 (99.6) |
| Male | 149 (53.6) | 169 (62.8) | 318 (58.1) |
| Female | 129 (46.4) | 100 (37.2) | 229 (41.9) |
| ECOG performance status | |||
| n | 279 (100.0) | 270 (100.0) | 549 (100.0) |
| 0 | 144 (51.6) | 146 (54.1) | 290 (52.8) |
| 1 | 112 (40.1) | 103 (38.1) | 215 (39.2) |
| 2 | 23 (8.2) | 21 (7.8) | 44 (8.0) |
| Baseline HSCT comorbidity index | |||
| n | 277 (99.3) | 267 (98.9) | 544 (99.1) |
| 0-1 | 154 (55.6) | 157 (58.8) | 311 (57.2) |
| 2 | 35 (12.6) | 28 (10.5) | 63 (11.6) |
| ≥3 | 88 (31.8) | 82 (30.7) | 170 (31.3) |
| AML type at baseline | |||
| n | 278 (99.6) | 268 (99.3) | 546 (99.5) |
| De novo AML | 196 (70.5) | 196 (73.1) | 392 (71.8) |
| Secondary AML | 82 (29.5) | 72 (26.9) | 154 (28.2) |
| ELN 2017 risk group | |||
| n | 248 (88.9) | 247 (91.5) | 495 (90.2) |
| Favorable | 64 (25.8) | 42 (17.0) | 106 (21.4) |
| Intermediate | 112 (45.2) | 119 (48.2) | 231 (46.7) |
| Adverse | 72 (29.0) | 86 (34.8) | 158 (31.9) |
| . | Treatment arm . | . | |
|---|---|---|---|
| DEC (n = 279) . | 3+7 (n = 270) . | Total (N = 549) . | |
| n (%) . | n (%) . | n (%) . | |
| Age, y | |||
| n | 279 (100.0) | 270 (100.0) | 549 (100.0) |
| 60-64 | 66 (23.7) | 65 (24.1) | 131 (23.9) |
| 65-69 | 119 (42.7) | 112 (41.5) | 231 (42.1) |
| ≥70 | 94 (33.7) | 93 (34.4) | 187 (34.1) |
| Sex | |||
| n | 278 (99.6) | 269 (99.6) | 547 (99.6) |
| Male | 149 (53.6) | 169 (62.8) | 318 (58.1) |
| Female | 129 (46.4) | 100 (37.2) | 229 (41.9) |
| ECOG performance status | |||
| n | 279 (100.0) | 270 (100.0) | 549 (100.0) |
| 0 | 144 (51.6) | 146 (54.1) | 290 (52.8) |
| 1 | 112 (40.1) | 103 (38.1) | 215 (39.2) |
| 2 | 23 (8.2) | 21 (7.8) | 44 (8.0) |
| Baseline HSCT comorbidity index | |||
| n | 277 (99.3) | 267 (98.9) | 544 (99.1) |
| 0-1 | 154 (55.6) | 157 (58.8) | 311 (57.2) |
| 2 | 35 (12.6) | 28 (10.5) | 63 (11.6) |
| ≥3 | 88 (31.8) | 82 (30.7) | 170 (31.3) |
| AML type at baseline | |||
| n | 278 (99.6) | 268 (99.3) | 546 (99.5) |
| De novo AML | 196 (70.5) | 196 (73.1) | 392 (71.8) |
| Secondary AML | 82 (29.5) | 72 (26.9) | 154 (28.2) |
| ELN 2017 risk group | |||
| n | 248 (88.9) | 247 (91.5) | 495 (90.2) |
| Favorable | 64 (25.8) | 42 (17.0) | 106 (21.4) |
| Intermediate | 112 (45.2) | 119 (48.2) | 231 (46.7) |
| Adverse | 72 (29.0) | 86 (34.8) | 158 (31.9) |
ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet.